Home » Stocks » INCY

Incyte Corporation (INCY)

Stock Price: $79.30 USD 0.68 (0.86%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $79.85 +0.55 (0.69%) Jul 23, 6:27 PM
Market Cap 17.46B
Revenue (ttm) 2.70B
Net Income (ttm) 478.48M
Shares Out 219.80M
EPS (ttm) 2.18
PE Ratio 36.36
Forward PE 23.98
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $79.30
Previous Close $78.62
Change ($) 0.68
Change (%) 0.86%
Day's Open 78.94
Day's Range 78.52 - 79.65
Day's Volume 854,411
52-Week Range 75.52 - 102.68

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

REGN vs. INCY: Which Stock Is the Better Value Option?

Other stocks mentioned: REGN
1 day ago - Zacks Investment Research

The recent downturn in Incyte Corporation's (NASDAQ:INCY) share price offers an entry opportunity, with the FDA likely to approve ruxolitinib in chronic GVHD indication in September 2021, according to B...

3 days ago - Benzinga

The FDA will not meet the PDUFA action date for Lilly (LLY) and Incyte's (INCY) sNDA for Olumaint to treat adults with atopic dermatitis.

Other stocks mentioned: LLY
4 days ago - Zacks Investment Research

INDIANAPOLIS, July 16, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) will not meet the Prescription Dru...

Other stocks mentioned: LLY
1 week ago - PRNewsWire

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Report Second Quarter Financial Results

1 week ago - Business Wire

Incyte Corporation (NASDAQ: INCY) has announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM). The study is jointly sponsored by Incy...

1 week ago - Benzinga

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #nejm--Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi) in Chronic Graft-Versus-Host Disease

1 week ago - Business Wire

The National Medical Products Administration (NMPA) of China has accepted for review Innovent Biologics Inc's (OTC: IVBIY) marketing application seeking approval for pemigatinib for cholangiocarcinoma. ...

Other stocks mentioned: IVBXF
2 weeks ago - Benzinga

Incyte (INCY) and MorphoSys (MOR) receive positive CHMP opinion for tafasitamab in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

3 weeks ago - Zacks Investment Research

REGN vs. INCY: Which Stock Is the Better Value Option?

Other stocks mentioned: REGN
3 weeks ago - Zacks Investment Research

Members of the Oncologic Drugs Advisory Committee recommended with a 13-4 vote to defer a regulatory decision on Incyte Corporation's (NASDAQ:INCY) retifanlimab until more data can be collected from a p...

4 weeks ago - Benzinga

If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union The positive opinion from the CHMP is base...

Other stocks mentioned: MOR
4 weeks ago - Accesswire

WILMINGTON, Del. & PLANEGG, Germany & MUNICH--(BUSINESS WIRE)---- $INCY--Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for Adults with Relapsed or ...

4 weeks ago - Business Wire

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Outcome of FDA ODAC Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

4 weeks ago - Business Wire

Delays in FDA approval for Incyte could spell good news for Sanofi.

Other stocks mentioned: ABBV, LLY, PFE, REGN, SNY
1 month ago - The Motley Fool

Incyte's (INCY) NDA review for ruxolitinib cream for the treatment of atopic dermatitis gets extended.

1 month ago - Zacks Investment Research

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference

1 month ago - Business Wire

REGN vs. INCY: Which Stock Is the Better Value Option?

Other stocks mentioned: REGN
1 month ago - Zacks Investment Research

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis

1 month ago - Business Wire

Incyte's (INCY) sNDA review of Jakafi for the indication of steroid-refractory chronic GVHD gets extended by three months.

1 month ago - Zacks Investment Research

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease (GVHD)

1 month ago - Business Wire

Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a ...

Other stocks mentioned: MOR
1 month ago - Accesswire

WILMINGTON, Del. & BOSTON--(BUSINESS WIRE)---- $INCY #ASCO21--Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

1 month ago - Business Wire

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

INDIANAPOLIS, June 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present data from post-hoc analyses that suggested OLUMIANT® (baricitinib) 4 mg tablet reduced...

Other stocks mentioned: LLY
1 month ago - PRNewsWire

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conferences

2 months ago - Business Wire

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO21--Positive Analysis from Phase 2 OPTIC Study of Ponatinib (Iclusig) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at ASCO 2021

2 months ago - Business Wire

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO21--Data from Incyte's Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting

2 months ago - Business Wire

Incyte (INCY) announces positive data from phase III studies on ruxolitinib cream for the treatment of vitiligo.

2 months ago - Zacks Investment Research

Incyte Corporation (NASDAQ: INCY) has announced positive topline results from its pivotal Phase 3 TRuE-V trial program evaluating ruxolitinib cream in adolescent and adult patients (age ≥12 years) with ...

2 months ago - Benzinga

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo.

2 months ago - Business Wire

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2021--Data from Incyte's Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress

2 months ago - Business Wire

PLANEGG, Germany & MUNICH & WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line T...

2 months ago - Business Wire

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal ...

Other stocks mentioned: MOR
2 months ago - Accesswire

CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), a clinical-stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces the appointme...

2 months ago - Business Wire

Incyte (INCY) beats earnings estimates in the first quarter but misses sales figure as Jakafi sales were weaker than expected.

2 months ago - Zacks Investment Research

Incyte Corporation (NASDAQ: INCY) reported Q1 earnings of $0.67, better than the consensus of $0.64, but sales of $604.7 million fell short of expectations of $659.2 million. Overall product and royalty...

2 months ago - Benzinga

Incyte (INCY) delivered earnings and revenue surprises of 3.08% and -7.77%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Incyte (NASDAQ:INCY) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 123.43% year over year to $0.67, which beat the estimate of $0.64.

2 months ago - Benzinga

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs

2 months ago - Business Wire

Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 months ago - Zacks Investment Research

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #SID2021--Incyte Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology Virtual Meeting 2021

2 months ago - Business Wire

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conference

2 months ago - Business Wire

Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports first-quarter 2021 results.

2 months ago - Zacks Investment Research

Incyte Corporation (NASDAQ: INCY) has announced findings from three pooled analyses of its Phase 3 studies, TRuE-AD1 and TRuE-AD2 evaluating ruxolitinib cream to treat atopic dermatitis (AD). Data prese...

3 months ago - Benzinga

INDIANAPOLIS, April 23, 2021 /PRNewswire/ -- Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE: LLY) and ...

Other stocks mentioned: LLY
3 months ago - PRNewsWire

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AADVMX2021--Incyte Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis

3 months ago - Business Wire

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AADVMX2021--Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo

3 months ago - Business Wire

Incyte (INCY) and MorphoSys begin dosing in a study evaluating tafasitamab or placebo, in combination Revlimid and Rituxan, in patients with relapsed or refractory FL or marginal zone lymphoma.

Other stocks mentioned: MOR
3 months ago - Zacks Investment Research

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AADVMX2021--Multiple Abstracts from Incyte's Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience

3 months ago - Business Wire

About INCY

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitin... [Read more...]

Industry
Biotechnology
IPO Date
Nov 4, 1993
CEO
Herve Hoppenot
Employees
1,773
Stock Exchange
NASDAQ
Ticker Symbol
INCY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 20 analysts, the average rating for Incyte stock is "Buy." The 12-month stock price forecast is 106.14, which is an increase of 33.85% from the latest price.

Price Target
$106.14
(33.85% upside)
Analyst Consensus: Buy